对于司美格鲁肽用于减肥的效果,目前是确切且显著的。根据NEJM关于司美格鲁肽和安慰剂双盲对照III期临床研究结果,司美格鲁肽用药68周后,体重变化的均值为-14.9%,中位减轻重量为15.3 kg。根据JAMA报道的司美格鲁肽vs.利拉鲁肽vs.安慰剂的III期临床研究结果,司美格鲁肽组体重变化的均值为-15.8%,显著优于利拉鲁肽...
We identified adults first dispensed tirzepatide or semaglutide labeled for T2D (as brand names Mounjaro [Eli Lilly] or Ozempic [Novo Nordisk], respectively) between May 1, 2022 (the month of tirzepatide approval) and September 30, 2023, and who had overweight (BMI ≥27 or a diagnosis co...
Mounjaro (tirzepatide): prescribing infor- mation. Indianapolis, IN: Eli Lilly; 2022. 14. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirze- patide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–16. https://doi.org/ 10.1056/NEJMoa2206038. 15. Fr´...